E-Mail
IMAGE: Activity of Neo™-L19 in F9 teratocarcinoma or WEHI-164 fibrosarcoma tumor bearing mice. (A) F9 teratocarcinoma. Left: Tumor bearing mice received 3 injections (?) of Neo™-L19, Neo™-KSF or saline (PBS) when...
view more
Credit: Correspondence to - Michael R. Mortensen - michael.mortensen@pharma.ethz.ch
Oncotarget recently published "Targeting an engineered cytokine with interleukin-2 and interleukin-15 activity to the neovasculature of solid tumors" by Mortensen, et al. which reported that there is a growing interest in the antibody-based delivery of cytokines to the tumor environment as a means to boost the anti-cancer activity of tumor-resident T cells and NK cells.